{"id":"W2145335139","doi":"10.1158/1078-0432.ccr-14-0114","title":"Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors","year":2014,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; Heart and Stroke Foundation of Canada","keywords":"Medicine; Tolerability; Adverse effect; Nausea; Pharmacokinetics; Internal medicine; Pharmacodynamics; Refractory (planetary science); Gastroenterology; Anorexia; Response Evaluation Criteria in Solid Tumors; Anemia; Pharmacology; Phases of clinical research; Toxicity","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009546757,0.001163702,0.001243347,0.0003539564,0.0002600476,0.0004705056,0.0005741527,0.0005324982,0.00146434],"category_scores_gemma":[0.0004649019,0.0003998101,0.0007556151,0.0003455336,0.000647239,0.0004607686,0.0002615534,0.002145905,0.0003900148],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007501488,"about_ca_system_score_gemma":0.001003718,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005495782,"about_ca_topic_score_gemma":0.001272203,"domain_scores_codex":[0.9997606,0.00009640373,0.0000145849,0.00004014879,0.0000390563,0.00004920033],"domain_scores_gemma":[0.9996257,0.00006304631,0.000113746,0.00003102394,0.00002486234,0.0001415261],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4306664,0.08956008,0.02082603,0.001338319,0.001448127,0.0003836844,0.0004810769,0.009117547,0.2684466,0.000354844,0.003307152,0.17407],"study_design_scores_gemma":[0.2919837,0.6413266,0.02933921,0.00005033157,0.0005999291,0.0004921107,0.00007028415,0.003724057,0.02914798,0.0001850265,0.003041899,0.00003890353],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972218,0.0009853189,0.0004003219,0.0000947956,0.00002698942,0.0005868777,0.000178419,0.00004090233,0.0004646066],"genre_scores_gemma":[0.9957765,0.0007788347,0.001377853,0.000273581,0.0000591692,0.0005781373,0.0006358174,0.000012077,0.0005080987],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00146434,"threshold_uncertainty_score":0.005442798,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09062321050583509,"score_gpt":0.4891884358991357,"score_spread":0.3985652253933006,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}